Induced Pluripotent Stem Cells Market (By Derived Cell Type: Hepatocytes, Fibroblasts; By Application: Drug Development; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Induced Pluripotent Stem Cells Market Size and Growth 2024 to 2033

The global induced pluripotent stem cells market size was estimated at around USD 1.73 billion in 2023 and it is projected to hit around USD 4.58 billion by 2033, growing at a CAGR of 10.23% from 2024 to 2033. Induced pluripotent stem cells (iPSCs) have revolutionized the field of regenerative medicine and research by providing a versatile and ethical alternative to embryonic stem cells. Derived from adult somatic cells through genetic reprogramming, iPSCs exhibit pluripotency, meaning they can differentiate into almost any cell type in the body. This capability makes iPSCs highly valuable for various applications, including disease modeling, drug discovery, and cell therapy.

Key Pointers

• North America dominated the global induced pluripotent stem cells market with the largest market share of 37% in 2023.
• Asia Pacific region is expected to grow at the fastest CAGR of 12.34% from 2024 to 2033.
• By Derived Cell Type, the fibroblasts contributed the largest market share of 31% in 2023.
• By Derived Cell Type, the hepatocytes segment is estimated to expand the fastest CAGR of 12.93% from 2024 to 2033.
• By Application, the drug development segment captured the largest market share of 50% in 2023.
• By Application, the tissue engineering and regenerative medicine segment is anticipated to grow at the noteworthy CAGR of 11.93% from 2024 to 2033.
• By End-Use, the pharmaceutical and biotechnology companies segment held the largest market share of 60% in 2023.
• By End-Use, the academic and research institutes segment is expected to grow at the fastest CAGR of 10.94% from 2024 to 2033.

What are the Growth Factors of Induced Pluripotent Stem Cells Market?

The growth of the induced pluripotent stem cells (iPSCs) market is propelled by an advancement in reprogramming technologies and culture methodologies have significantly improved the efficiency and safety of iPSC production. Innovations such as the development of non-integrative reprogramming methods and optimized culture conditions have made iPSCs more accessible and reliable for research and therapeutic applications. Additionally, the expanding scope of iPSC applications—ranging from disease modeling and drug screening to personalized medicine and regenerative treatments—is driving market expansion. The increasing prevalence of chronic and genetic diseases underscores the need for effective therapies and personalized treatment solutions, further fueling interest in iPSC-based approaches. Moreover, substantial investments in stem cell research from both public and private sectors, along with supportive regulatory frameworks, are enhancing the overall growth trajectory of the iPSC market.

What are the Trends in Induced Pluripotent Stem Cells Market?

• Rising Adoption in Drug Discovery and Development: iPSCs are increasingly utilized for drug discovery and development due to their ability to model human diseases more accurately than traditional methods. Pharmaceutical companies are incorporating iPSC technology to identify potential drug candidates and assess their efficacy and safety in human-like cell models.
• Expansion in Regenerative Medicine: There is a growing trend towards using iPSCs in regenerative medicine for developing personalized cell-based therapies. Advances in cell differentiation techniques are facilitating the creation of patient-specific cells for tissue repair and replacement, enhancing the potential for tailored treatments.
• Integration with Advanced Technologies: The integration of iPSCs with technologies such as gene editing (e.g., CRISPR/Cas9) and 3D bioprinting is gaining momentum. These combined approaches are expected to accelerate the development of customized cell therapies and improve tissue engineering outcomes.
• Increased Focus on Ethical and Regulatory Aspects: As iPSC technology advances, there is a growing emphasis on addressing ethical and regulatory concerns. This includes ensuring the safety and quality of iPSC-derived products and navigating the complex regulatory landscape to facilitate clinical translation.

What are the Key Challenges Faced by Induced Pluripotent Stem Cells Market?

• High Production Costs: The generation and maintenance of iPSCs involve complex and expensive processes. High costs associated with cell reprogramming, culture media, and quality control can be a significant barrier for widespread adoption and commercialization.
• Safety and Quality Concerns: Ensuring the safety and quality of iPSC-derived products remains a major challenge. Risks such as genetic abnormalities, potential for tumor formation, and inconsistent differentiation outcomes must be carefully managed to meet regulatory standards and ensure patient safety.
• Regulatory Hurdles: The regulatory landscape for iPSC-based therapies is complex and varies across regions. Navigating the stringent requirements for clinical trials and approvals can be time-consuming and costly, potentially delaying the market entry of new therapies.
• Ethical and Privacy Issues: The use of iPSCs raises ethical and privacy concerns, particularly regarding the source of the somatic cells and the handling of genetic information. Addressing these concerns is crucial for gaining public trust and ensuring ethical practices.

Which Region Dominates the Induced Pluripotent Stem Cells Market?

North America led the market with a 37% share in 2023, driven by a robust research infrastructure and substantial public and private funding for biotechnology and healthcare. The region’s strong support for stem cell research and therapies contributes significantly to its market dominance.

What is the Contribution of North America to Induced Pluripotent Stem Cells Market?

In Europe, the iPSC market is growing due to robust R&D activities in biology, pharmaceuticals, and therapeutics, coupled with the presence of key market players. This growth reflects Europe's strong emphasis on research and development.

In Asia Pacific, the iPSC market is expected to grow at the fastest CAGR of 12.34% from 2024 to 2033. This rapid growth is attributed to increased government support for the healthcare sector and rising awareness of cell therapies and personalized medicine.

Derived Cell Type Insights

In 2023, fibroblasts led the market with a dominant share of 31%. These cells, being the most accessible in the skin, are increasingly pivotal in cell therapy due to their regenerative capabilities. Dermal fibroblasts are crucial for synthesizing extracellular matrix components like glycosaminoglycans and collagens, which maintain the skin's structural integrity. Preclinical studies have demonstrated the effectiveness of allogeneic and autologous dermal fibroblasts in treating burn ulcers, wound healing, and genetic skin disorders. The potential of iPSCs derived from fibroblasts and gene-edited fibroblasts as treatments for skin issues is driving significant market growth.

The hepatocytes segment is projected to experience the highest growth rate, with a CAGR of 12.93% from 2024 to 2033. This growth is attributed to the rising incidence of liver disorders, sedentary lifestyles, and increased alcohol consumption. According to the National Institutes of Health (NIH), liver disease was responsible for one in every 25 deaths globally in March 2023, equating to two million deaths annually and accounting for 4% of all deaths, with men representing nearly two-thirds of these fatalities.

Application Insights

In 2023, the drug development segment captured the largest market share of 50%. The World Health Organization (WHO) reports that non-communicable diseases, including cardiovascular disorders, cancer, chronic respiratory diseases, and diabetes, claim 41 million lives annually. This high prevalence underscores the need for extensive disease research. iPSCs are instrumental in disease modeling, facilitating the discovery and development of new treatments. For instance, Evotec SE has established an iPSC infrastructure to support efficient and reproducible drug screening.

The tissue engineering and regenerative medicine segment is anticipated to grow at the fastest rate, with a CAGR of 11.93% from 2024 to 2033. Although iPSC applications for tissue development are still emerging, their potential to generate any cell or tissue type makes them crucial for treating conditions such as spinal cord injuries, leukemia, and heart disease. These cells can also be used to create genetically matched, rejection-proof tissues for transplantation, thereby advancing the market.

End-Use Insights

The pharmaceutical and biotechnology companies segment held the largest market share of 60% in 2023. These companies are investing heavily in developing stem cell-based therapies to leverage the commercial potential of iPSCs. For example, Fate Therapeutics announced in October 2022 that it would present preclinical and clinical results from various iPSC product platforms at the Society for Immunotherapy of Cancer (SITC) meeting in November 2022, highlighting a robust iPSC product pipeline and supporting market growth.

The academic and research institutes segment is expected to grow at the fastest rate, with a CAGR of 10.94% over the forecast period. iPSCs are increasingly used in academic and clinical research due to their therapeutic potential. For instance, the University of Minnesota expanded its clinical trials in August 2020 to explore engineered iPSC-derived natural killer cells for treating COVID-19. Additionally, Indiana University researchers began a study in March 2022 to investigate the use of human iPSCs to restore vision in diabetic patients. The growing research environment for evaluating iPSC-based treatments is likely to drive further market expansion.

Who are the Top Manufactures in Induced Pluripotent Stem Cells Market?

• STEMCELL Technologies Inc.
• Cellular Engineering Technologies Inc.
• REPROCELL Inc.
• Takara Bio, Inc.
• Axol Bioscience Ltd.
• Fate Therapeutics, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• Cynata Therapeutics Limited
• Evotec SE
• Astellas Pharma Inc.

Recent Developments

• In October 2023, QHP Capital acquired Applied StemCell, aiming to significantly boost the manufacturing capacity for various cell types, including induced pluripotent stem cells (iPSCs).
• In September 2023, Ushio, Inc. partnered with Axol Bioscience to source iPSC-derived sensory neuron cells. This collaboration enabled Ushio to integrate human iPSC-derived axoCells sensory neurons into its in vitro Nerve Plate platform.
• In February 2023, Lineage Cell Therapeutics, Inc. teamed up with Eterna Therapeutics, Inc. to develop beta 2 microglobulin (B2M)-deficient iPSC lines. These new cell lines, developed by Eterna, are set to enhance Lineage’s product offerings for treating specific central nervous system (CNS) disorders and other neurological conditions.
• In January 2022, Bristol-Myers Squibb Company established a strategic partnership with Century Therapeutics to advance iPSC-derived allogeneic cell therapy. This collaboration was anticipated to strengthen Bristol-Myers Squibb’s portfolio in stem cell-based therapies.

Induced Pluripotent Stem Cells Market Segmentation:

By Derived Cell Type

• Hepatocytes
• Fibroblasts
• Keratinocytes
• Amniotic Cells
• Others

By Application

• Drug Development   
• Tissue Engineering & Regenerative Medicine
  • Neurology
  • Orthopedics
  • Oncology
  • Cardiovascular and Myocardial Infraction
  • Diabetes
  • Others
• Toxicology Research 
• Disease Modeling

By End-use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• MEA